Alcon Inc.
Financials
Valuation Metrics
Alcon Inc.'s Market Cap is $31.72B. At end of 2025 it was $38.56B. Ranked #444 of 3,121 in US market (top 14%), #313 of 1,658 on NYSE (top 19%), #30 of 205 in Health Care Equipment & Services (top 15%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $31.72B | US#444/3,121 Sec#30/205 |
| Revenue | $10.75B | US#538/3,121 Sec#35/205 |
| Net Income | $639M | US#728/3,121 Sec#40/205 |
| Total Assets | $31.10B | US#463/3,121 Sec#22/205 |
| Net Assets | $21.59B | US#226/3,121 Sec#13/205 |
| Employees | 25,000 | US#452/3,121 Sec#33/205 |
| Value | ||
| P/E | 49.61x | US#1,916/3,121 Sec#100/205 |
| P/B | 1.47x | US#863/3,121 Sec#46/205 |
| P/S | 2.95x | US#1,693/3,121 Sec#115/205 |
| EV/EBITDA | 17.16x | US#1,736/3,121 Sec#77/205 |
| FCF Yield | 5.31% | US#1,355/3,121 Sec#62/205 |
| Profitability | ||
| ROE | 2.96% | US#1,975/3,121 Sec#104/205 |
| ROA | 2.06% | US#1,626/3,121 Sec#98/205 |
| Op. Margin | 10.26% | US#1,577/3,121 Sec#75/205 |
| Revenue Growth | 7.19% | US#1,565/3,121 Sec#111/205 |
| Earnings Growth | -40.42% | US#1,687/3,121 Sec#87/205 |
| Financial Health | ||
| Debt Ratio | 44.00% | US#497/3,121 Sec#54/205 |
| Total Debt | $5.30B | US#654/3,121 Sec#30/205 |
| FCF | $1.68B | US#410/3,121 Sec#26/205 |
| Cash | $1.35B | US#563/3,121 Sec#30/205 |
| Current Ratio | 2.09x | US#1,183/3,121 Sec#106/205 |
| Net Debt/EBITDA | 1.90x | US#1,290/3,121 Sec#78/205 |
| Dividend | ||
| Div. Yield | 0.57% | US#1,503/3,121 Sec#41/205 |
| Div. Growth | 27.69% | US#203/3,121 Sec#5/205 |
| Performance | ||
| 1Y Return | -16.39% | US#2,282/3,121 Sec#154/205 |
| 1M Return | -12.42% | US#2,562/3,121 Sec#175/205 |
| From 52W High | -25.79% | US#1,820/3,121 Sec#126/205 |
| 1Y MDD | -28.86% | US#1,343/3,121 Sec#56/205 |
| Trading | ||
| Volume | 3,275,050 shares | US#835/3,121 Sec#46/205 |
| Trading Value | $213M | US#675/3,121 Sec#55/205 |
| Per Share | ||
| EPS | $1.31 | US#1,580/3,121 Sec#83/205 |
| BPS | $44.28 | US#530/3,121 Sec#37/205 |
Company Info
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates through two segments, Surgical and Vision Care. It offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. The company’s cataract products include Unity CS, LenSx laser system, Verion reference unit and Verion digital marker, ARGOS biometer, SMARTCATARACT health platform, NGENUITY 3D visualization system, LuxOR surgical ophthalmic microscope, and ORA system for intra-operative measurements; ADI cloud-based platform; and implantable products, including monofocal, Toric, and Presbyopia-Correcting IOLs, as well as delivery systems, such as AutonoMe and UltraSert. In addition, it provides Custom Pak surgical procedure packs vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, Grieshaber, MIVS instruments; scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit probes; and refractive surgery products, including WaveLight and Contoura Vision used for LASIK refractive procedure. Further, the company offers daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.